Please login to the form below

Not currently logged in
Email:
Password:

Rydapt

This page shows the latest Rydapt news and features for those working in and with pharma, biotech and healthcare.

One hit, one miss as FDA panel votes on Daiichi’s cancer drugs

One hit, one miss as FDA panel votes on Daiichi’s cancer drugs

Novartis’ Rydapt (midostaurin) was the first FLT3 inhibitor to reach the market in 2017, and is used alongside chemotherapy for newly-diagnoses FLT3-positive AML.

Latest news

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics